Atenolol vs. Losartan in people with Marfan syndrome

Atenolol vs. Losartan in people with Marfan syndrome

Robert (R Jay) J. Widmer, M.D., Ph.D., Cardiovascular Diseases, and Juan M. Bowen, M.D., director of the Marfan Syndrome and Thoracic Aorta Clinic at Mayo Clinic's campus in Rochester, Minnesota, compare losartan vs. atenolol for reducing the aortic dilation rate and discuss the results of the Atenolol Versus Losartan in Children and Young Adults With Marfan's Syndrome study, published in the New England Journal of Medicine in November 2014.

A related editorial by Dr. Bowen and Heidi M. Connolly, M.D., Cardiovascular Diseases, appears in the same issue: Of Marfan's Syndrome, Mice, and Medication.


Created by

Mayo Clinic